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Abstract
Distressing symptoms such as hot flashes and sleep disturbances affect over 70% of women 
approaching menopause for an average of 4–7 years, and recent large cohort studies have shown 
that anxiety and stress are strongly associated with more severe and persistent hot flashes and can 
induce hot flashes. Although high estrogen doses alleviate symptoms, extended use increases 
health risks, and current non-hormonal therapies are marginally better than placebo. The lack of 
effective non-hormonal treatments is largely due to the limited understanding of the mechanisms 
that underlie menopausal symptoms. One mechanistic pathway that has not been explored is the 
wake-promoting orexin neuropeptide system. Orexin is exclusively synthesized in the estrogen 
receptor rich perifornical hypothalamic region, and has an emerging role in anxiety and 
thermoregulation. In female rodents, estrogens tonically inhibit expression of orexin, and estrogen 
replacement normalizes severely elevated central orexin levels in postmenopausal women. Using 
an ovariectomy menopause model, we demonstrated that an anxiogenic compound elicited 
exacerbated hot flash-associated increases in tail skin temperature (TST, that is blocked with 
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estrogen), and cellular responses in orexin neurons and efferent targets. Furthermore, systemic 
administration of centrally active, selective orexin 1 or 2 and dual receptor antagonists attenuated 
or blocked TST responses, respectively. This included the reformulated Suvorexant, which was 
recently FDA-approved for treating insomnia. Collectively, our data support the hypothesis that 
dramatic loss of estrogen tone during menopausal states leads to a hyperactive orexin system that 
contributes to symptoms such as anxiety, insomnia, and more severe hot flashes. Additionally, 
orexin receptor antagonists may represent a novel non-hormonal therapy for treating menopausal 
symptoms, with minimal side effects.
Keywords
Orexin; Hypocretin; Hypothalamus; Hot flash; Estrogen; Menopause; Thermoregulation; 
Cutaneous; Serotonin; Norepinephrine
1. Introduction
Menopause occurs following loss of ovarian function during natural aging, and a simulated 
menopausal state follows some breast and ovarian cancer treatments [e.g., surgical 
oophorectomy, or estrogen inhibition therapies (Carpenter and Andrykowski, 1999; 
Gallicchio et al., 2006)]. Common symptoms during menopausal states include vasomotor 
symptoms (hot flashes and night sweats), anxiety and mood disruption, and sleep 
disturbances (Kronenberg, 1990). Hot flashes are the cardinal symptom, and 75% of 
postmenopausal women surveyed reported repeated hot flash episodes over an average of 4–
7 years, but some over 10–13 years (Avis et al., 2015; Politi et al., 2008) following onset of 
menopause. Hot flash symptom presentations correlate well with objectively measurable, 
sympathetically-induced increases in cutaneous blood flow that raises skin temperature 
(Low et al., 2008).
Hormone replacement therapy [HRT, containing estradiol (E2) in combination with estrone 
(E1) and progesterone (P)] remains the most effective therapy for reducing hot flash 
symptomatology by ~75% treating in peri and post menopausal women[see systematic 
review (Maclennan et al., 2004)]. Yet, E2 replacement therapy (ERT) alone is as effective as 
HRT at moderate doses (1–2 mg) (Baerug et al., 1998; Greendale et al., 1998) which restore 
plasma estrogen levels to 85–100% of pre-menopausal levels, respectively (Waaseth et al., 
2008).
Although ERT effectively alleviates hot flashes [even at lower doses of 0.5 mg (Joffe et al., 
2014)], not all women are interested in taking ERT since initial use of E2 is associated with 
side effects such as uterine bleeding and breast tenderness (Maclennan et al., 2004), and 
long term ERT also increases the risk for estrogen positive breast cancer (Beral and Million 
Women Study, 2003; Bolland et al., 2015). Additionally, ERT is contraindicated for 
postmenopausal women with estrogen receptor positive breast cancer and hot flashes are the 
primary reason for noncompliance with estrogen inhibition therapies (Kemp et al., 2014), 
which increases mortality (Hershman et al., 2011). Collectively these side effects and 
identified risks may explain a significant decline in HRT prescription and compliance (Zbuk 
and Anand, 2012) and an increase interest in non-hormonal therapies. Unfortunately, the few 
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existing non-hormonal therapies are much less effective than ERT (Nelson et al., 2006). For 
instance, ERT reduces hot flash symptomatology by by ~75% [see systematic review 
(Maclennan et al., 2004)], whereas clonidine or serotonin/norepinephrine reuptake inhibitors 
(SSRI/NRI) are ~46% and 30% effective, respectively and are only marginally better than 
placebo responses that typically range from 20 to 50% (Nelson et al., 2006). These therapies 
are also commonly associated with side effects such as headaches, nausea, decreased sexual 
function, and insomnia, which can reduce adherence. The lack of effective, non-hormonal 
treatments is largely due to the limited understanding of the mechanisms that underlie 
menopausal symptoms. Menopausal symptoms are clearly induced by estrogen withdrawal; 
yet, how loss of estrogens leads to menopausal symptoms is largely unknown (Miller and Li, 
2004).
One mechanistic pathway that has not been explored is the orexin (OX and its two forms, 
OXA and OXB) neuropeptide system, which is unique in that OX-synthesizing neurons are 
restricted to the perifornical hypothalamic (PeF) region of rodents (Peyron et al., 1998) and 
humans (Thannickal et al., 2007). Estrogen receptors are expressed in the PeF (Laflamme et 
al., 1998), and stimulating the PeF in humans also produces symptoms associated with 
menopause [e.g., feelings of anxiety, racing heart, and hot flashes or chills (Wilent et al., 
2011)]. Additionally, in female rats, E2 administration decreases OXA content within the 
hypothalamus as well as at postsynaptic target CNS sites (Russell et al., 2001). More 
importantly, menopausal women have 300% higher plasma OX levels compared to 
reproductive controls, which is restored following Prempac, comprised primarily of equine 
estrones, and norgestrel, a form of progestin (El-Sedeek et al., 2010)]. This dramatic 
increase in OX activity during menopause is likely contributing to disrupted sleep since 
OX’s most prominent role is to promote wakefulness (Sakurai, 2007), and higher OXA 
concentrations in cerebrospinal fluid have been demonstrated in individuals with poor sleep 
quality (Allen et al., 2002). But there is also emerging evidence that a hyperactive OX 
system contributes to anxiety states and panic-associated sympathetic activity in rodents 
(Johnson et al., 2012a, 2015, 2010), and that central OX levels are elevated in patients with 
increased anxiety symptoms (Johnson et al., 2010). These findings, combined with the 
building evidence that anxiety and stress are strongly associated with more severe and 
persistent hot flashes in large cohort studies (Avis et al., 2015), and that stressful stimuli can 
increase objective hot flashes (Swartzman et al., 1990) led to our current hypothesis that 
“the OX system plays a critical role in menopause-related symptoms such as hot flashes, 
anxiety, and sleep disruption”. We further posited that anxiety states and panicogenic-related 
stimuli may contribute to hot flash severity and frequency, and could help explain the 
presence of hot flashes in thermoneutral environments.
To test these hypotheses, we: (1) determined whether a pan-icogenic compound would elicit 
exacerbated tail skin temperature (TST: a correlate of a hot flash) responses in a surgical 
ovariec-tomy (OVEX) model of a menopausal state; (2) assessed cellular responses in OX 
neurons and efferent neurochemically identified targets that regulate arousal, anxiety, and 
thermoregulation; and (3) assessed orexin gene expression in the PeF, and determined if 
systemically treating OVEX rats with highly selective and brain-penetrant antagonists that 
target the two cognate OX receptors at optimal pharmacokinetic timelines would attenuate 
panicogenic drug induced TST responses.
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2. Materials and methods
2.1. Animals and housing conditions
Adult female (225–250 g) Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) 
were housed individually in plastic cages in standard housing conditions (maintained at 
22°C) for 5 days prior to experimental procedures. Rats had ad libitum access to food and 
water and were maintained on a 12:12 light/dark cycle (lights on at 07:00 h). All 
experiments were conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals, Eighth Edition (Institute for Laboratory Animal Research, The 
National Academies Press, Washington, DC, 2011) and the guidelines of the IUPUI 
Institutional Animal Care and Use Committee.
2.2. Ovariectomy (OVEX) and sham OVEX surgeries
All surgical procedures were conducted under sterile conditions. Rats were anesthetized 
under isoflurane delivered through a nose cone (2–3% by volume MGX Research Machine, 
Vetamac, Rossvile, IN dissolved in medical air, Praxair, Indianapolis, IN). Animals were 
checked for corneal and paw-withdrawal reflexes to ensure adequate anesthesia before 
commencing surgical procedures. The skin was shaved on each side between the ribcage and 
hindlimbs and sterilized with iodine solution. A small (1–2 cm) incision was made to expose 
the lateral muscle wall, which was then opened and the ovaries were visualized. The ovaries 
are a prominent, spherical, reddish-pink structure that are readily seen from the incision site. 
In the even that the ovaries were not readily visible, a cotton swab was used to carefully 
move overlying tissue to expose them. For OVEX rats, after visualization, the ovary was 
gently pulled up and the fallopian tube was clamped 3–5 mm under the ovary with a 
hemostat. A length of suture was used to tie off the tube under the clamp, and the ovary was 
removed with a scalpel. The tissue was inspected for bleeding and re-tied if necessary. Silk 
sutures were used to close the muscle wall and the skin was closed with surgical staples. The 
entire procedure was then repeated on the other side. For sham operated control rats, after 
ovary visualization, the muscle wall and skin were closed as for OVEX rats and procedure 
repeated on the other side. Following surgery, all rats were given pain medication 
(buprenorphine, Indiana University School of Medicine Laboratory Animal Resources) and 
monitored until consciousness was restored. Animals then recovered for the next 12 days in 
the animal housing facilities, and were monitored daily.
2.3. Assessments of tail and core body temperature
For assessments of TST, a thermistor (cat. no. 5SRTC-TT-K-30-36; Omega Engineering, 
Stamford, CT) was secured 1 cm from the tail base to the ventral side using 3 M Durapore® 
tape. The thermistor was attached to a T-type pod and connected to a Powerlab data 
acquisition system (LabChart software, ADInstruments, Colorado Springs, CO) for 
continuous monitoring of temperature. Infrared thermal images were acquired using a FLIR 
T440 thermal imaging camera (FLIR Systems, Boston, MA). For assessments of core body 
temperature (CBT), a radiotelemetry probe with an internal thermistor was implanted into 
the abdominal cavity (model HD-S11, Data Sciences International, St. Paul, MN) under 
isoflurane. The probe was held in place with sutures into the muscle wall (during the 
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ovariectomy surgery). Probes were interfaced with DataQuest ART software (DSI) for 
continuous recording of temperature.
2.3.1. Experiment 1—subthreshold panicogenic drug effect on TST of OVEX 
rats+/−estrogen—Female rats were anesthetized under isoflurane, and the ovaries were 
visualized (for sham controls) and excised bilaterally for OVEX rats. Twelve days post 
surgeries, OVEX rats received daily subcutaneous (s.c.) injections of either sesame oil 
vehicle (0.2 ml, sham-OVEX received this as well) or 17-β estradiol (0.25 mg/kg in 10% 
DMSO/90% sesame oil; Sigma–Aldrich, St. Louis MO) for 5 days prior to testing. Once a 
baseline was established for TST, rats were injected intraperitoneally (i.p.) with either 
vehicle or a low dose of the panicogenic drug FG-7142 (3 mg/kg, dissolved in 10% 
DMSO/90% ultrapure H2O). FG-7142 is a partial inverse agonist at the GABAA receptor, 
which decreases central GABA-mediated inhibition. We have also previously shown that 
systemically injecting males with a higher dose of FG-7142 (7.5 mg/kg) increases panic-
associated behavioral and cardioexcitatory responses and cellular responses in anxiety/panic 
brain circuitry (e.g., amygdala and orexin neurons in PeF) (Johnson et al., 2012c). A 
systemic OX1 receptor antagonist also attenuates FG-7142-induced panic-associated 
behavioral and cardioexcitatory responses and cellular responses in the anxiety/panic 
circuitry(Johnson et al., 2012c). The experiment utilized a crossover design such that all rats 
received either vehicle or panicogenic drug with 48 h between treatments.
2.3.2. Experiment 2—subthreshold panicogenic drug effect on TST and CBT in 
OVEX rats—Female rats were anesthetized under isoflurane and the ovaries were excised 
bilaterally and allowed 12 days’ recovery. Radiotelemetry probes that contained an internal 
thermistor were also implanted into the abdominal cavity. Probes were interfaced with 
DataQuest ART software (DSI) for continuous recording of temperature. Once a baseline for 
TST and CBT was established, rats were injected intraperitoneally (i.p.) with either vehicle 
or FG-7142 (3 mg/kg) while monitoring TST and CBT simultaneously. The experiment 
utilized a crossover design such that all rats received either vehicle or FG-7142 with 48 h 
between treatments.
2.3.3. Experiments 3–4—neurochemical system cellular responses in OVEX 
rats treated with a panicogenic drug—Female rats were anesthetized under 
isoflurane, and the ovaries were visualized (for sham controls) and excised bilaterally for 
OVEX rats. Following 12 days, OVEX and sham-OVEX rats were injected with either 
vehicle or a low dose of FG-7142 (1 mg/kg, i.p.). Ninety minutes post-injection, rats were 
anesthetized with isoflurane and transcardially perfused with 4% paraformaldehyde in 0.1 M 
sodium phosphate buffer (PB). Brains were removed, post-fixed in the same fixative for 
12h, rinsed twice in PB (12 h), and placed in 0.1 M PB containing 30% sucrose for 12 h. 
Brains were blocked using a standard adult rat brain matrix (model RBM-4000C, ASI 
Instruments, Warren, MI) and frozen using liquid isopentane cooled by liquid nitrogen. 
Serial coronal sections (30 μm) were cut using a Leica freezing microtome and were 
immediately placed in cryoprotectant consisting of 27% ethylene glycol and 16% glycerol in 
0.05 M PB to yield 6 alternative sets of sections. Sections were stored at −20&#°C until 
immunohistochemical processing. All solutions used had pH level of 7.4.
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We used immunohistochemical staining for c-Fos, in the presence or absence of other 
neurochemical markers, to identify specific brain regions involved in responses to the 
anxiogenic drug. Immunostaining of nuclear c-Fos expression is a useful method of 
identifying functional cellular responses to anxiety-related stimuli (Johnson et al., 2012a). 
Four of the six alternate sets of 30 μm coronal brain sections were immunostained, one set 
each for c-Fos (full brain), or c-Fos (day 1) then on day 2 the tissue was immunostained with 
the cytoplasmically expressed OXA (hypothalamus); tyrosine hydroxylase (TH, brainstem), 
or tryptophan hydroxylase (TPH, brainstem). Immunostaining of OXA, TH, and TPH were 
done to identify orexin, noradrenergic, and serotonergic neurons, respectively. Specifically, 
free-floating sections were washed in 0.05 MPBS for 30 min, then incubated in 1% H2O2 in 
PBS for 20 min. Sections were then washed 10 min in PBS and 20 min in PBS with 0.3% 
Triton X-100 (PBST). Sections were then incubated 12–16 h in PBST with the primary 
antibody solution at room temperature [i.e., day 1: c-Fos (rabbit anti-c-Fos polyclonal 
antibody, cat. no. sc-52, Santa Cruz Biotech., Santa Cruz, CA; diluted 1:10,000); day 2: 
OXA (rabbit anti-OXA-polyclonal, affinity-purified antibody, cat. no. H-003-30, Phoenix 
Pharmaceuticals, Burlingame, CA; diluted 1:8000); TH (rabbit anti-TH polyclonal affinity-
purified antibody cat. no. AB152, Millipore, Billerica, MA; diluted 1:800); or TPH (sheep 
anti-TPH polyclonal affinity-purified antibody, cat. no. 9260–2505, AbD Serotec; diluted 
1:1000 for midbrain/pons and 1:2000 for medulla)]. After a 30 min wash in PBST, sections 
were incubated 2 h in the appropriate secondary antibody: biotinylated goat anti-rabbit IgG 
(c-Fos, OXA, TH; cat no. BA-1000, Vector Laboratories, Burlingame, CA; diluted 1:200), 
biotinylated rabbit anti-sheep IgG (TPH; cat. no BA-6000; Vector Laboratories, 1:200 
dilution). Sections were washed again for 30 min in PBST then incubated 1.5 h in an avidin-
biotin complex provided in a standard Vector Elite kit (cat no. PK-6100, Vector 
Laboratories; diluted 1:500). Substrates for chromagen reactions were SG (c-Fos; SK-4700, 
Vector Laboratories) or 0.01% 3,3′-diaminobenzidine tetrahydrochloride (DAB; OXA, TH; 
TPH) (D-5637, Sigma, St. Louis MO, USA) in PBS containing 0.003% H2O2, pH 7.4. 
Substrate reactions were run for ~10–15 min. All sections were mounted in 0.1% gelatin 
dissolved in ultrapure water on glass slides, dried overnight, dehydrated and mounted with 
coverslips using DPX mounting medium (BDH Laboratory Supplies, Poole, UK). All 
washes and incubations were done in 12 well polystyrene plates with low frequency shaking 
on an orbital shaker.
2.3.4. Experiment 5—orexin, glutamate, GABA gene expression in the PeF of 
OVEX rats—Twelve days after sham/OVEX surgery, rats were anaesthetized and brains 
removed and flash frozen in isopentane precooled with dry ice then sored at −80°C until 
ready for processing. The PeF region was bilaterally dissected from two consecutive 300 μm 
coronal sections and tissue was processed for absolute qRT-PCR for Orexin mRNA using 
methods previously described (Johnson et al., 2010), or for glutamate and GABA-related 
genes using the custom-designed TaqMan Low Density Array (TLDA) as previously 
described (Truitt et al., 2015). Orexin gene expression analysis was normalized to beta-actin 
as previously described (Johnson et al., 2010). The glutamate and GABA-related gene 
expression panel was normalized using geNorm approach as previously described in detail 
(Truitt et al., 2015).
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2.3.5. Experiments 6–7—effects of an OX1R antagonist (SB-334867) or 
estradiol on anxiety-like behaviors in OVEX rats
2.3.5.1. Experiment 6: Following 12 days, OVEX and sham-OVEX rats were injected i.p. 
with a control vehicle [0.2 ml/100 g volume dimethyl sulfoxide (DMSO)] or a 30 mg/kg 
dose of the single OX1R antagonist (SORA1) SB334867 (cat. no. 1960, Tocris Bioscience, 
Bristol, UK, in 0.2 ml/100 g volume DMSO) which has selectivity of 50X for the OX1 
receptor compared to the OX2 receptor; occupies 100% of central OX1Rs within 30 min 
post systemic injection (Bonaventure et al., 2015); and attenuates FG-7142 (7.5 mg/kg, i.p.) 
induced anxiety-like behavior and panic-associated cardioex-citatory responses without 
inducing somnolence (Johnson et al., 2012a). Therefore, we tested rats in an accepted test of 
anxiety-associated behaviors (i.e., open field test which was videorecorded and scored by 
Anymaze software, Stoelting, Woods Dale, IL) 60 min following injections. The experiment 
utilized a crossover design such that all rats received either vehicle or the SORA1 with 48 h 
between treatments.
2.3.5.2. Experiment 7: Following 12 days, OVEX rats received daily subcutaneous 
injections of either sesame oil vehicle (0.2 ml, sham-OVEX received this as well) or 17-β 
estradiol (0.25 mg/kg) for 5 days prior to testing in the open field.
2.3.6. Experiment 8–12—effects of an OX1R (SB-334867 or Compound 56), 
OX2R (TCS OX2 29 or JNJ10397049) or dual OXR antagonist (DORA-12) on 
TST responses to an panicogenic drug in OVEX rats—Following 12 days, all 
OVEX rats were pretreated systemically with highly selective and centrally active OXR 
antagonists (details below) prior to receiving an injection of the panicogenic drug FG-7142 
(3 mg/kg, i.p.). These experiments utilized a crossover design such that all rats received 
either vehicle or an OXR antagonist with 48 h between treatments. Five days prior to 
experiments, rats were handled for 5 min and trained with either i.p or s.c injections or mock 
gavages. Tail skin temperature was assessed as previously described.
2.3.6.1. Experiment 8—dual orexin receptor antagonist (DORA; DORA-12): On the 
experimental day, rats received an oral gavage of a control vehicle (0.2 ml/100 g volume 
20% vitamin E/TPGS) or 30 mg/kg of a dual OXR antagonist, DORA-12 (Merck & Co.) 
with balanced potency for OX1R and OX2R; good brain exposure; 47% oral bioavailability; 
and a favorable brain to plasma ratio of 0.4–0.6. This compound is a close structural analog 
of suvorexant, and the 30 mg/kg p.o. dose of DORA-12 being used here achieves a plasma 
Cmax of 2.02 μM with CSF exposure of 66 nM and ex vivo occupancy of 97%, and has 
been shown to promote sleep in rats (Gotter et al., 2013).
2.3.6.2. Experiments 9—single orexin-1 receptor antagonist (SORA1; SB-334867): On 
the experimental day, rats received an i.p. injection of a control vehicle (0.2 ml/100 g 
volume DMSO) or a 30 mg/kg dose of SB-334867 i.p.
2.3.6.3. Experiment 10—single orexin-1 receptor antagonist (SORA1; Compound 56): 
All rats were injected s.c. with a control vehicle (0.2 ml/100 g volume DMSO) or the highly 
selective SORA1, Compound 56 (10 mg/kg), dissolved in 30% SBE-β-cyclodextrin/70% 
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ddH2O supplied byJanssen Research & Development, LLC, La Jolla, CA, which has 44X 
selectivity for the OX1R compared to the OX2R, and the 10 mg/kg systemic dose occupies 
~90% of central OX1Rs within 30 min (Bonaventure et al., 2015). While SB334867 has 
been shown to have off-target affinities for non-OXRs, in a binding assay panel of 50 
receptors, ion channels, and transporters, Compound 56 did not exhibit a significant affinity 
to anything other than the OX1R (Bonaventure et al., 2015).
2.3.6.4. Experiments 11—single orexin 2 receptor antagonist (SORA2; JNJ10397049): 
All rats were injected s.c. with a control vehicle (0.2 ml of 10% pharmasolve, 5% solutol, 
and 85% dextrose in water) or a dose of JnJ10397049 (10 or 30 mg/kg, Tocris Bioscience, 
Bristol, UK, in 0.2 ml) which has selectivity of 630X for the OX2R compared to the OX1R 
and the 30 mg/kg systemic dose occupies ~80% of central OX2Rs within 30 min (Dugovic 
et al., 2009).
2.3.6.5. Experiment 12—single orexin 2 receptor antagonist (SORA2, TCS OX229): All 
rats were injected i.p. with a control vehicle (0.9% saline) or TCS OX2 29 (30 mg/kg, Tocris 
Bioscience, in 0.2 ml), a SORA2 that displays >250-fold selectivity for OX2Rs over OX1Rs 
(Bonaventure et al., 2015).
2.4. Statistical analyses
Analyses of behavior (SORA1), and TST responses were analyzed using an ANOVA with 
drug treatments and/or surgical treatments as main factors (i.e., independent variables) and 
time as a repeated measure. In the presence of a significant drug effect or drug × time 
interaction, an ANOVA was run at each time point in combination with a Fisher’s LSD test 
post hoc test to detect within subject differences. Analyses of OXA gene expression and 
behavior (estrogen) were performed with an independent two-tailed t-test or a non-
parametric Mann-Whitney Rank Sum Test U if unequal variance was detected with a 
Shapiro-Wilk normality test p< 0.05. Expression of each glutamate/GABA-related gene was 
calculated relative to the sham treatment group using the delta Ct method. These values were 
then converted to log10 (log10(ΔΔCt)) for statistical analyses with an ANOVA and Fisher’s 
LSD for post hoc testing. Analyses of cell counts was analyzed with an ANOVA with drug 
treatment and surgical treatments as main factors and a Tukey’s post hoc test. Levene’s Test 
of Equality of Error Variance was also done to determine equal variances in the groups to 
determine if nonparametric testing was needed. The alpha level was set at 0.05 in all cases. 
All statistical analyses were carried out using SPSS 21.0 (SPSS Inc., Chicago, IL, USA), 
and all graphs were generated using SigmaPlot 12.0 (SPSS Inc.) and an illustration program 
(CorelDraw X5, Ontario, Canada).
3. Results
3.1. Experiment 1: OVEX rats have exacerbated TST responses to a low dose of a 
panicogenic drug that is blocked by estrogen replacement
Compared to sham-OVEX controls, systemically injecting female OVEX rats with a low 
dose of the panicogenic drug FG-7142 (n = 7,5,5) produced a marked 6–7°C increase in 
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TST, which was blocked with estrogen replacement (Fig. 1a-representative thermal imaging; 
Fig. 1b-treatment × time interaction F(55,770) =3.4, p< 0.001).
3.2. Experiment 2: FG-7142 induced increases in TST precedes a decrease in core body 
temperature (CBT) decrease in OVEX rats
Compared to vehicle treated OVEX controls, FG-7142 treated OVEX rats had a dramatic 
increase in TST within 3 min (F(55,825) = 18.7, p< 0.0001, n = 8,9, see thermal imaging of 
tail in Fig. 2a, and TST response on bottom line graphs in Fig. 2b) which was followed by a 
decrease in CBT that occurred 11 min post injection (F(55,825) = 11.2, p < 0.001, n = 8,9, see 
CBT response on top line graphs in Fig. 2b).
3.3. Experiment 3: neural circuits of OVEX rats that display hyperactive responses 
following a low dose of a panicogenic drug
Among the brain regions implicated in menopause-related symptoms (see Fig. 3a for 
convergent evidence for brain region involvement and Fig. 3b for coronal illustration of 
brain regions assessed), the following brain regions of OVEX rats showed exacerbated 
cellular c-Fos responses to the low dose of a panicogenic drug FG-7142 (i.e., OVEX × 
FG-7142 interaction, Fig. 3c): (1) PeF [n = 7,7,7,7, F(1,24) = 4.5, p = 0.044]; (2) central 
amygdala [CeA, n = 7,7,6,7 (area damaged unilaterally on one rat), F(1,23) = 16.1, 0.001]; 
(3) dorsolateral region of dorsal raphe nucleus [DRVL, n = 6,6,7,7, (area damaged 
unilaterally on two rats), F(1,22) = 6.6, p = 0.018]; (4) locus ceruleus [LC, n = 7,7,7,7, F(1,24) 
= 6.1, p = 0.021]; (5) raphe pallidus [RPa, n = 7,7,7,7, F(1,24) = 7.4, p = 0.012]; (6) 
rostroventrolateral medulla [RVLM, n = 7,7,7,7, F(1,24) = 4.4, p = 0.048]. Cellular responses 
were not significantly different in the periventricular hypothalamic nucleus (PVN), medial 
preoptic hypothalamic area (mPOA), basolateral, lateral, or medial amygdala (BLA, LA, 
MeA), bed nucleus of the stria terminalis (BNST), dorsome-dial or dorsolateral 
periaqueductal gray (dmPAG, dlPAG), ventral or dorsal part of the dorsal raphe nucleus 
(DRV or DRD), median raphe nucleus (MRn), or raphe magnus (RMg).
3.4. Experiment 4: neurochemical circuits of OVEX rats that display hyperactive responses 
following a low dose of a panicogenic drug
Neurochemical phenotyping of c-Fos responses in OXA-ir neurons in the PeF and adjacent 
lateral hypothalamus (LH) revealed that OX neurons in the PeF, but not LH had exacerbated 
responses to FG-7142 in OVEX rats (n = 6,6,7,7) [PeF: OVEX × drug interaction, F(1,22) = 
4.1, p = 0.055; OVEX effect, F(1,22) = 4.1, p = 0.055; FG-7142 effect F(1,22) = 4.5, p = 0.046; 
LH data not shown: OVEX × drug interaction, F(1,22) = 1.1, p = 0.306; OVEX effect, F(1,22) 
= 2.0, p = 0.169; FG-7142 effect F(1,22) = 0.5, p = 0.482] (Fig. 4a). This difference in the 
number of c-Fos-ir OXA positive neurons was unlikely due to differences in numbers of 
OXA-ir neurons counted since there was no difference in the PeF [see gray bars in Fig. 4a: 
PeF: OVEX × drug interaction, F(1,22) = 0.9, p = 0.770; OVEX effect, F(1,22) = 0.3, p = 
0.601; FG-7142 effect F(1,22) = 0.9, p = 0.770; LH: OVEX × drug interaction, F(1,22) = 1.3, 
p = 0.258; OVEX effect, F(1,22) = 3.2, p = 0.086; FG-7142 effect F(1,22)< 0.01, p = 0.997].
Neurochemical phenotyping of c-Fos responses of tyrosine hydroxylase-ir (TH)-
noradrenergic neurons in the LC revealed that these neurons had exacerbated responses to 
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FG-7142 in OVEX rats [Fig. 4b, OVEX × drug interaction, F(1,22) = 3.8, p = 0.064; OVEX 
effect, F(1,22) = 7.2, p = 0.014; FG-7142 effect F(1,22) = 10.1, p = 0.004]. Neurochemical 
phenotyping of c-Fos responses TPH-ir serotonergic neurons in the DRVL and RPa revealed 
that these neurons had exacerbated responses to FG-7142 in OVEX rats [Fig. 4c, n = 6,6,7,7, 
OVEX × drug interaction, F(1,23) = 9.4, p = 0.006 (area damaged unilaterally on two rats); 
Fig. 4d, n = 7,6,7,6, OVEX × drug interaction, F(1,22) = 14.7, p = 0.001 (area damaged on 
two rats)]. No difference was noted in the total number of TH or TPH-ir neurons counted 
between groups (see gray bars in Fig. 4c and d).
3.5. Experiment 5: orexin, glutamate, GABA gene expression in the PeF of OVEX rats
Gene expression analyses in the PeF region (see Fig. 3a for convergent evidence of PeF 
region involvement) revealed that compared to sham-OVEX controls, OVEX rats had 200% 
higher expression of prepro-orexin (n = 7,6, see Fig. 5a for illustration of area 
micropunched; Fig. 5b, t(14) = −2.1, p = 0.029). A TaqMan Low Density Array (TLDA) 
custom designed for GABA and glutamate-related genes revealed that compared to sham-
OVEX rats, OVEX rats had had a 1.81 fold increased gene expression of GAD1 (aka 
GAD67, p = 0.040) and decreased expression of Grm4 (−1.83 fold; p = 0.003) and Grin2a 
(−1.63 fold; p = 0.024) (see volcano plot in Fig. 5c).
3.6. Experiments 6–7: systemicpretreatment with a SORA1 or estrogen is anxiolytic in 
OVEX rats
Compared to sham-OVEX controls, OVEX rats spent less time exploring the center region 
of an open field test (indicating an anxiety-like behavioral response, Suppl. Fig. 1a). 
Furthermore, pretreating OVEX rats with a SORA1 blocked the OVEX-induced anxiety-
associated behavior [SORA1 effect, F(1,35) = 7.1, p = 0.012, n = 10,10,9,10, an outlier 
detected and removed from OVEX/vehicle group, Grubb’s test z = 2.3, p<0.05]. In a second 
experiment, compared to OVEX rats treated with vehicle, OVEX rats with estrogen 
replacement spent more time exploring the center of the open field [Suppl. Fig. 1b, n = 9,7, 
failed Shapiro–Wilk normality test p<0.05, Mann–Whitney Rank Sum Test U= 5.0, p = 
0.006].
3.7. Experiments 8–12: systemic pretreatment with an OX1R, OX2R, or dual OX antagonist 
attenuates TST responses to a panicogenic drug in OVEX rats
Here the highest dose of DORA-12 blocked the TST response to the panicogenic drug 
FG-7142 (Fig. 6a); drug × time interaction, F(108,1458) = 1.4, p = 0.006, n = 9,10,10]. In the 
SORA1 experiments, both SB334867 and Compound 56 attenuated the TST response to the 
panicogenic drug FG-7142 (Fig. 6b); no drug × time interaction F(55,715) = 1.1, p = 0.247, 
but there was a significant drug effect, F(1,13) = 7.6, p = 0.016, n = 5,10; Fig. 6c, drug × time 
interaction F(54,648) = 2.2, p< 0.001, F(1,13) = 7.6, p = 0.016, n = 7,7]. Initially, we 
administered a SORA2 (TCS OX2 29, 5 and 10mg/kg, i.p.) which, compared to vehicle 
group, did not alter FG-7142 induced TST responses in OVEX rats (data not shown, drug × 
time interaction F(130,2535) = 0.5, p = 1.00, drug effect F(2,39) = 0.5, p = 0.600, n = 
14,14,14). We later learned that this compound only achieves about ~50% OX2R occupancy 
and quickly dissociates (P. Bonaventure, personal communication). In a subsequent 
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experiment using a brain penetrant SORA2 called JnJ10397049, which achieves greater 
(~75%) and sustained (8 h) receptor occupancy an attenuation of the TST response to the 
panicogenic drug FG-7142 (3mg/kg, i.p.) was observed at both doses [Fig. 6d; drug × time 
interaction F(100,1950) = 37.4, p< 0.001, n = 14,14,14].
4. Discussion
Here we first ovariectomized female rats to model a surgical menopausal state, which 
increased baseline anxiety-associated behaviors, and when challenged with a low dose of the 
panicogenic compound FG-7142, OVEX rats had an exacerbated hot flash-associated TST 
responses >7°C that preceded a decrease in CBT (suggesting a heat dissipation response), 
thus providing face validity. Furthermore, ER, which also attenuated anxiety-associated 
behaviors, almost blocked the TST responses. Thus, predictive validity is provided since ER 
effectively treats hot flashes and FG-7142 is known to cause hot flashes and/or chills in 
humans, and also elicits anxiety (Dorow et al, 1983). These data also suggest that there is a 
loss of GABAergic inhibitory signaling following loss of ovarian function. Consistent with 
this hypothesis is that in one clinical study the benzodiazepine oxazepam was effective in 
reducing hot flashes in a cohort of premenopausal women who underwent oophorectomy 
(Erkkola et al, 1973). Collectively, these clinical studies and our preclinical studies may 
explain part of the effectiveness of these treatments for hot flashes. Finally, since this 
method of inducing hot flash-associated TST responses also produces strong anxiety at 
higher doses, it suggests that some stress-related stimuli and or existing anxiety states could 
contribute to hot flash severity and prevalence.
The link between anxiety and stress with hot flashes has been controversial. For instance, 
although a recent systematic review concluded that anxiety symptoms were low during the 
menopause transition, they noted that the majority of studies utilized brief and largely non-
validated measures of anxiety symptoms (Bryant et al., 2011). Bryant and colleagues further 
stated that studies that utilized accepted diagnostic assessments did observe an increase in 
anxiety in postmenopausal women [see (Cagnacci et al, 1997; Pimenta et al., 2012)] that is 
alleviated with ERT + P (Cagnacci et al., 1997). Furthermore, greater presence of anxiety 
predicts more frequent and/or severe hot flashes (Freeman et al., 2005), and is also 
positively correlated with hot flash severity (Gibson et al., 2011). Additionally, women with 
premenstrual syndrome, which includes high levels of anxiety, are more likely to have hot 
flashes (Freeman et al, 2004) and hot flashes are common symptom associated with panic 
attacks that occur in severe anxiety disorders (DSM-V). Perhaps more compelling is that in a 
recent large (n = 3302) multiracial/multiethnic longitudinal investigation [the Study of 
Women’s Health Across the Nation], greater perceived stress, anxiety symptoms, depressive 
symptoms, and decreased socioeconomic status were associated with more persistent and 
frequent vasomotor symptoms (Avis et al., 2015). Thus, these data are supportive of the 
hypothesis that anxiety and stress, which are associated with more severe and persistent hot 
flashes, may also contribute to hot flash severity and prevalence. This hypothesis is also 
consistent with a hypothetical review that observed similarities between hot flashes and 
severe anxiety/panic attacks that included: symptom presentation; neurochemical circuitry; 
pharmacotherapy; and psychological treatments (Hanisch et al, 2009) and also suggests that 
neurochemical systems implicated in generating anxiety-associated emotional, behavioral, 
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and physiological responses may represent novel targets for treating symptoms associated 
with menopause.
Our subsequent experiments sought to determine if the hypothalamic OX system might 
represent one such novel therapeutic target. In a series of experiments, we demonstrated that 
rats with a surgical menopausal state have a two-fold increase in prepro-OX mRNA 
expression within the PeF region, and exacerbated OX neuronal responses to a subthreshold 
panicogenic drug that excites this system (FG-7142) (Johnson et al., 2012a). We further 
demonstrated that efferent targets of OX neurons heavily implicated in hot flash etiology 
(Freedman et al, 1990; Stearns et al, 2005) also showed exacerbated cellular responses. 
These included limbic structures such as the amygdala, as well as noradrenergic neurons in 
the locus ceruleus, and serotonergic neurons in the dorsal raphe nucleus and raphe pallidus. 
Artificially increasing central OX activity in rodents with intracerebroventricular injections 
of OXs disrupts sleep (Espana et al., 2002); increases anxiety-associated behaviors (Suzuki 
et al., 2005); induces thermoregulatory changes (Yoshimichi et al, 2001); elicits cardio-
excitation (Samson et al., 1999), and stimulates corticosteroid release (Brunton and Russell, 
2003), which is related to greater hot flash symptomatology in menopausal women (Woods 
et al., 2006)]. These data are consistent with preclinical data showing that estrogen inhibits 
OX expression in rodents (Russell et al, 2001), and clinical data showing OX activity is 
dramatically elevated following menopause (El-Sedeek et al, 2010). Thus, a hyperactive OX 
system seen here in our surgically-induced menopausal state in rodents and mirrored in 
postmenopausal women (El-Sedeek et al., 2010) could be contributing to multiple core 
symptoms that occur during and/or following menopause. An outstanding question for 
future studies, would be determining if the interactions observed between orexin and 
estrogen are indirect or direct (e.g., determining if the prepro-orexin gene has an estrogen 
response element, or whether expression of ERα and/or ERβ are colocalized with orexin 
neurons).
In a final series of experiments, we systemically treated OVEX rats with highly selective 
and brain-penetrant OXR antagonists at optimal pharmacokinetic timepoints to determine if 
antagonizing this system would decrease hot-flash associated increases in TST. There are 
two forms of OXs, OXA and OXB, and two known receptors. The OX1R has greater 
affinity for OXA than OXB by an order of magnitude, while the OX2R has similar affinity 
for both OXA and OXB (Sakurai, 2007). Both receptors are G-protein coupled, and are 
either co-located or selectively located in specific brain areas (Marcus et al, 2001), 
suggesting differentiated roles. Here we show that a dual OXR antagonist, DORA-12 (a 
reformulated version of Suvorexant) blocked the TST response elicited by FG-7142, 
whereas antagonizing either receptor alone partly attenuated hot flash-associated TST 
responses. This suggests that these drugs may provide a novel non-hormonal treatment 
strategy for hot flashes in menopausal women. Interestingly, Suvorexant was recently FDA-
approved with an indication for insomnia. Sleep problems, broadly defined, are a known 
problem at midlife and at the menopause (Burleson et al, 2010), and many have posited that 
hot flashes during sleep contribute to nighttime awakenings/sleep problems. Therefore, it 
seems reasonable to postulate that targeting either symptom may lead to improvement in the 
other. The sleep-promoting properties of DORAs are primarily through antagonism of 
OX2Rs which are exclusive to histaminergic neurons in the tuberomammillary nucleus, 
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which is a brain region that plays a critical role in wake promotion (Huang et al., 2001; 
Marcus et al., 2001), but also plays a role in regulating thermogenic activity (Yasuda et al., 
2004) which could partially explain the ability of the OX2R antagonist to attenuate TST 
responses. The anxiolytic effects of DORAs may be preferentially through antagonism of 
OX1Rs (Bonaventure et al., 2015; Johnson et al., 2012a, 2015a, 2010), but also potentially 
OX2Rs (Li et al., 2010). Anatomically, OX1Rs appear to be more selectively expressed in 
panic and anxiety-associated neural circuits such as the bed nucleus of the stria terminalis, 
amygdala, cingulate cortex and exclusively in noradrenergic neurons in the locus ceruleus 
[(Marcus et al., 2001), see review (Johnson et al., 2012b)], which also play a role in 
sympathetic mobilization. Yet, anxiolytic effects of ORX2R antagonism have been 
demonstrated in the paraventricular thalamus (Li et al., 2010). Thus, DORAs may alleviate 
sympathetically-mediated hot flashes and or hot flashes resulting from pre-existing anxiety 
states or in responses to some stress-related stimuli.
5. Conclusion
Collectively, our previous and current data support the hypothesis that estrogen tonically 
inhibits the orexin arousal system, and dramatic loss of estrogen tone during menopausal 
states leads to a hyperactive orexin system that contributes to the cardinal menopausal 
symptoms such as recurrent hot flashes, insomnia, and anxiety. Additionally, our data 
suggests that OXR antagonists, possibly in combination with lower doses of ERT, may 
represent a novel non-hormonal therapy for treating all of these symptoms, with minimal 
side effects.
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Fig. 1. 
Rats with surgical menopause are vulnerable to displaying hot-flash associated cutaneous 
vasomotor responses to a low dose of a panicogenic drug.
Effects of a low dose of FG-7142 (3 mg/kg) on tail skin temp of female sham-OVEX rats 
given daily 0.2 ml s.c. injections of sesame oil control vehicle (n = 7), or in OVEX rats 
given daily s.c. injections of control vehicle (n = 5) or 0.25 mg/kg 17-β estradiol (n = 5). (a) 
Thermal images of rats 10 min after FG-7142 injection from each treatment group with scale 
bar to right. (b) Line graph with error bars (SEM) represents the mean tail skin temp prior to 
and following a 3 mg/kg i.p. injection of FG-7142 in each treatment group assessed with a 
thermistor at base of tail. *Denotes significance with a one-way ANOVA with drug as an 
independent variable and time as a repeated measures p < 0.05, and significant differences 
between groups using a Fisher’s LSD post hoc test protected by an ANOVA at each time 
point, p< 0.05.
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Fig. 2. 
Panicogenic drug-induced cutaneous vasomotor responses precede a decrease in core body 
temperature in rats with surgical menopause.
Effects of a low dose of FG-7142 (3 mg/kg) on tail skin temp and core body temperature of 
female OVEX rats. (a) Representative thermal images of OVEX rats 10 min after vehicle or 
FG-7142 injection from each treatment group with scale bar to right. (b) Line graph with 
error bars (SEM) represents the mean tail skin temp and core body temperature of OVEX 
rats prior to and following systemic injections of either vehicle (n = 8) or 3 mg/kg FG-7142 
(n = 9). *Denotes significance with a one-way ANOVA with drug as an independent 
variable and time as a repeated measures p<0.05, and significant differences between groups 
using a Fisher’s LSD post hoc test protected by an ANOVA at each time point, p< 0.05.
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Fig. 3. 
Rats with surgical menopause display hyperactive cellular responses following a low dose of 
a panicogenic drug in neural circuits heavily implicated in menopausal symptoms. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.)
(a) Table with convergent evidence of neurochemical circuit involvement in hot flash-
associated cutaneous vasomotor responses. Columns respectively represent brain regions 
and additive criteria to strengthen the likelihood that a particular brain region will be 
impacted by loss of estrogen, but also involved in menopause-related symptoms. Closed 
circles means the region meets the criterion, open circles mean the region does not meet the 
criterion. Yellow shaded rows meeting most criterion, with orange and purple shaded rows 
meeting less. See results section for anatomical abbreviation definitions. Effects of vehicle 
or a dose of FG-7142 (that evokes hot flashes in OVEX, but not sham rats) on cellular 
responses (c-Fos immunoreactive, ir) in brain regions from OVEX and sham-OVEX rats 
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from table 1 (n = 6,6,7,7). (b) illustrates coronal brain sections of a rat at different 
rostrocaudal levels, with yellow circles indicating brain regions where OVEX rats showed 
hyperactive responses to FG-7142 compared to sham-OVEX rats. Purple circles indicate 
areas that were counted but had no significant differences between groups. Bars in(c) 
represent mean number of single c-Fos-ir cells + -SEM. *Denotes significant differences 
between groups using aTukey’s HSD post hoc test protected by 2 way ANOVA, p < 0.05.
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Fig. 4. 
Neurochemical circuits of rats with surgical menopause that display hyperactive responses 
following a low dose of a panicogenic drug.
Effects of vehicle or FG-7142 injection (that evokes hot flashes in OVEX, but not sham rats) 
on cellular responses (c-Fos immunoreactive, ir) in brain regions from OVEX and sham-
OVEX rats from table 1 (n = 6,6,7,7). Bars in (a) represent c-Fos + OX double labelled 
neurons in the PeF/DMN and LH. Bars in (b) represent c-Fos + tyrosine hydroxylase (TH) 
in noradrenergic neurons in the locus ceruleus (LC). Bars in (c and d) represent c-Fos + 
tryptophan hydroxylase (TPH) in serotonergic neurons in the ventrolateral region of the 
dorsal raphe nucleus (DRVL/VLPAG), and in the raphe pallidus (RPa), respectively. 
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*Denotes significant differences between groups using Tukey’s HSD post hoc test p< 0.05, 
protected by a 2 way ANOVA. Photographs in (a–d) represent high magnification brain 
sections illustrating dark nuclear immunostaining of c-Fos +-brown cytoplasmic 
immunostaining of OX-ir neurons in the PeF, TH-ir neurons in the LC, and TPH-ir neurons 
in the DRVL/VLPAG and RPa from sham and OVEX rats treated with FG-7142, 
respectively. Scalebar in d = 20 μm.
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Fig. 5. 
Surgical menopause enhances baseline hypothalamic OX/glutamate gene expression. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.)
(a) Illustration of a coronal section of rat hypothalamus with the PeF/DMNand LH with 
representative distribution of OX neurons (black dots) and areas where micropunches were 
done (orange dashed circles) in a 300 μm fresh frozen tissue section for gene expression data 
in (b and c) and where cell counts were done (purple dashed lines) in Figs. 2 C and 3). (b) 
Indicates expression of prepro-OX mRNA in sham and OVEX rats. *Indicates p < 0.05 
unpaired t-test. (c) A volcano plot of hypothalamic mRNA levels of OVEX rats relative to 
sham rats, determined by a custom designed TaqMan Low Density Array (TLDA). Plotted 
on the y-axis are p values from Fisher’s LSD test (each gene) and ±fold difference (Log10) 
on the x-axis. Genes with p< 0.05 are indicated by solid circles and all others are open 
circles. Horizontal red line is p = 0.05 and vertical dotted lines represent a ±2 fold change in 
expression (0.0301 on log10 scale).
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Fig. 6. 
Systemically treating ovariectomized rats with centrally active orexin 1 and/or 2 receptor 
antagonists attenuates hot flash associated cutaneous vasomotor responses to a low dose of a 
panicogenic compound.
(a) Effects of FG-7142 (3 mg/kg) on tail skin temp of female OVEX rats orally pre-treated 
with vehicle or a dual OXR antagonist (DORA-12. 10 and 30mg/kg p.o.); (b and c) Effects 
of FG-7142 (3 mg/kg) on tail skin temp of female OVEX, or sham-OVEX rats systemically 
pre-treated with vehicle or an OX1R antagonist (b: SB334867 30 mg/kg i.p.; c: compound 
56,3 mg/kg s.c); (d) Effects of FG-7142 (3 mg/kg) on tail skin temp of female OVEX, or 
sham-OVEX rats systemically pre-treated with vehicle or an OX2R antagonist 
(JnJ-10397049,10 and 30 mg/kg s.c). *Denotes significant differences between groups using 
a two-tailed Dunnett’s post hoc test against vehicle protected by a one-way ANOVA with 
drug as main factor and time as repeated measures, and a Fisher’s LSD post hoc test 
protected by a one-way ANOVA at each time point, p< 0.05. All OX receptor antagonist 
doses, routes, and treatment timelines were done based on published pharmacokinetic 
information (e.g., brain penetrance, OX1R and OX2R occupancy in the brain, and Cmax in 
plasma and brain).
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